Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine - Quiz - MDSpire

Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine

  • By

  • Antonietta Liotti

  • Giorgia Teresa Maniscalco

  • Anne Lise Ferrara

  • Valeria Mazzone

  • Maedeh Dehbozorgi

  • Annamária Szabó

  • Martina Belardo

  • Daria Marcogiuseppe

  • Antonio De Martino

  • Maria Elena Di Battista

  • Giovanna Servillo

  • Ornella Moreggia

  • Daniele Di Giulio Cesare

  • Vincenzo Andreone

  • Gilda Varricchi

  • Veronica De Rosa

  • June 16, 2026

  • 0 min

Share

Original Source(s)

Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine

  • by Antonietta Liotti, Giorgia Teresa Maniscalco, Anne Lise Ferrara, Valeria Mazzone, Maedeh Dehbozorgi, Annamária Szabó, Martina Belardo, Daria Marcogiuseppe, Antonio De Martino, Maria Elena Di Battista, Giovanna Servillo, Ornella Moreggia, Daniele Di Giulio Cesare, Vincenzo Andreone, Gilda Varricchi, Veronica De Rosa

  • June 16, 2026

Related Content

Epstein-Barr Virus-Associated Multiple Sclerosis: Recent Mechanistic Advances and Clinical Therapeutic Perspectives

HLA-DRB1*15:01 drives sex- and age-dependent microglial immune phenotypes and neuroimmune signaling

Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis